TrialCancer2011
Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma.
Ruben Niesvizky et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
56 papers cite it
this papertrialcites it